Treatment with secukinumab for plaque psoriasis in patients with infectious comorbidities and latent tuberculosis: A multi‐case report analysis
Open Access
- 28 January 2022
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 10 (1) , e05302
Abstract
Three patients affected by plaque psoriasis and presenting with multiple infectious comorbidities and latent tuberculosis infection (LTBI) were initially managed with conventional DMARD therapy. After showing unsuccessful results, treatment with secukinumab was initiated without prophylactic isoniazid and soon led to favorable dermatological outcomes without the reactivation of tuberculosis infection.Keywords
This publication has 14 references indexed in Scilit:
- Evidenced-based guidelines for tuberculosis screening before biologic treatment initiationJournal of the American Academy of Dermatology, 2020
- Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA StudyAdvances in Therapy, 2020
- Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available EvidenceDermatology and Therapy, 2020
- Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance dataArthritis Research & Therapy, 2019
- Psoriasis: Which therapy for which patientJournal of the American Academy of Dermatology, 2019
- The risk of tuberculosis in patients with psoriasis treated with anti‐tumor necrosis factor agentsInternational Journal of Dermatology, 2015
- Targeting of interleukin-17 in the treatment of psoriasisClinical, Cosmetic and Investigational Dermatology, 2014
- Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 InfectionPLOS Pathogens, 2014
- Psoriasis prevalence among adults in the United StatesJournal of the American Academy of Dermatology, 2014
- Mice genetically inactivated in interleukin‐17A receptor are defective in long‐term control of Mycobacterium tuberculosis infectionImmunology, 2013